UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average	burden				
hours per response	0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	•												·		
Name and Address of Reporting Person Lin Patrick]	2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106			3. Date of Earliest Transaction (Month/Day/Year) 12/31/2021						X_Officer (give title below) Other (specify below) Chief Business - Strategy Off						
(Street) HANOVER, MD 21076			4. If Amendment, Date Original Filed(Month/Day/Year) 01/04/2022					_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City)		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned			ned								
1.Title of Sec (Instr. 3)	curity	I	Date	2A. Deeme Execution any (Month/Da	Date,	if Coo (Ins		(A)	cecurities Accor Disposed ir. 3, 4 and 5	of (D) Ow Tra (Ins		,		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Re	eport on a se	Sarate fine for each	Class of Securities		,		,	Persons	d in this fo	rm are not	required	of information of inf	d unless tl		1474 (9-02)
Reminder: Re	eport on a se	parate fine for each	class of securities		,			Persons	d in this fo	rm are not	required	l to respon	d unless tl		1474 (9-02)
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year	Table II - 1 (3A. Deemed Execution Date,	Derivative (e.g., puts, of 4. Transac Code	Securicalls,	rities A warrai 5. Num	acqui nts, o aber tive ties ed	Persons	d in this for blays a current of of, or Ber ertible securcisable ion Date	rm are not rently valid reficially Ov	required d OMB co wned l Amount ing	8. Price of	d unless tl	of 10. Owners Form of	11. Natur of Indirect Beneficia Ownersh : (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 1 (3A. Deemed Execution Date, 1) any	Derivative (e.g., puts, of 4. Transac Code	Securicalls, etion	rities A warran 5. Num of Derivat Securiti Acquire (A) or	acqui nts, o aber tive ies ed	Persons contained form dispred, Dispose ptions, converse and Expirate	d in this for blays a current of of, or Ber ertible securcisable ion Date	rm are not rently valid reficially Overities) 7. Title and of Underlyst Securities	required d OMB co wned l Amount ing	8. Price of Derivative Security	9. Number Derivative Securities Beneficially Owned Following	of 10. Owners Form of Derivati Security Direct (or Indir	11. Natur of Indired Beneficia ve (Unstr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 1 (3A. Deemed Execution Date, 1) any	Derivative (e.g., puts, of 4. Transac Code	Securicalls, etion	rities A warrar 5. Num of Derivat Securiti Acquire (A) or Dispose of (D) (Instr. 3 and 5)	acqui nts, o aber tive ies ed	Persons contained form dispred, Dispose ptions, converse and Expirate	d in this foolays a curl d of, or Ber ertible securcisable ton Date t/Year)	rm are not rently valid reficially Overities) 7. Title and of Underlyst Securities	required d OMB co wned l Amount ing	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Owners Form of Derivati Security Direct (or Indirects)	11. Natur of Indired Beneficia ve (Unstr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Lin Patrick C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076			Chief Business - Strategy Off			

Signatures

/s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact	01/06/2022
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.
- (2) This Amendment is being filed to correct the balance in Box 9 this should have reflected a cumulative balance.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.